|
Oct 6
|
3 Magnificent Dividend Stocks to Buy in October
|
|
Oct 6
|
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
|
|
Oct 5
|
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
|
|
Oct 4
|
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
|
|
Oct 4
|
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
|
|
Oct 4
|
Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
|
|
Oct 4
|
AbbVie’s atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA
|
|
Oct 3
|
AbbVie cuts 2024 profit forecast citing R&D expenses
|
|
Oct 3
|
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
|
|
Oct 3
|
PGIM Jennison Health Sciences Fund Sold AbbVie (ABBV) in Q2. Here’s Why
|
|
Oct 3
|
Investors in AbbVie (NYSE:ABBV) have seen impressive returns of 235% over the past five years
|
|
Oct 3
|
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
|
|
Oct 2
|
Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
|
|
Oct 2
|
5 Best Dividend Growth Stocks to Buy in October
|
|
Oct 2
|
Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
|
|
Oct 2
|
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
|
|
Oct 1
|
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
|
|
Oct 1
|
AbbVie to Host Third-Quarter 2024 Earnings Conference Call
|
|
Sep 30
|
AbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 Years
|
|
Sep 30
|
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
|